fbpx Pubblicazioni in evidenza | Istituto di Candiolo - FPO - IRCCS
Nat Genet. Stromal contribution to the colorectal cancer transcriptome.
Science Tran. Med. IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies
Lancet Oncol. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.
Cancer Discov. Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution.
Cancer Res. MET-Mediated Resistance to EGFR Inhibitors: An Old Liaison Rooted in Colorectal Cancer Stem Cells.
Nature Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.
Cancer Research MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors.
Science Trasl. Med. Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer
J.Clin.Oncol. Liquid Biopsies: Genotyping Circulating Tumor DNA.
Molecular Oncology An ‘in-cell trial’ to assess the efficacy of a monovalent anti-MET antibody as monotherapy and in association with standard cytotoxics


Raggiungi l'Istituto di Candiolo


  •  Indirizzo per navigatori: Strada Provinciale 142 di Piobesi incrocio Strada Statale 23 del Sestriere  -  Coordinate: 44°58'01.6"N 7°34'00.0"E